Prof Gary Connett
MB ChB DCH MD FRCPCH
Consultant Respiratory Paediatrician, Professor of Paediatric Respiratory Medicine
Profile page(s)
Prof Connett is a Professor of Paediatric Respiratory Medicine at the University of Southampton. He leads the Regional Paediatric Cystic Fibrosis (CF) Service, and is a specialist respiratory paediatrician accepting referrals from across the South of England.
His research interests include CF microbiology, adherence, the benefits of exercise in CF, testing the efficacy of new CF treatments and assessing their impacts on future care needs. He is particularly interested in the extent to which asthma might be an autonomic, cue and context conditioned response occurring as a result of antenatal and early childhood factors and the implications this has for clinical care.
Landmark publications:
Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials. Keogh RH, Cosgriff R, Andrinopoulou ER, Brownlee KG, Carr SB, Diaz-Ordaz K, Granger E, Jewell NP, Lewin A, Leyrat C, Schlüter DK, van Smeden M, Szczesniak RD, Connett GJ. Thorax. 2021 Sep 23:thoraxjnl-2020-216265. doi: 10.1136/thoraxjnl-2020-216265.
Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Causer AJ, Shute JK, Cummings MH, Shepherd AI, Wallbanks SR, Pulsford RM, Bright V, Connett G, Saynor ZL. Pediatr Pulmonol. 2022 Jul 18. doi: 10.1002/ppul.26078. Epub ahead of print. PMID: 35851858.
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis, Kevin W. Southern, Carlo Castellani, Elise Lammertyn, Alan Smyth, Donald VanDevanter, Silke van Koningsbruggen-Rietschel, Jürg Barben, Amanda Bevan, Edwin Brokaar, Sarah Collins, Gary J. Connett, Thomas W.V. Daniels, Jane Davies, Dimitri Declercq, Silvia Gartner, Andrea Gramegna, Naomi Hamilton, Jenny Hauser, Nataliya Kashirskaya, Laurence Kessler, Jacqueline Lowdon, Halyna Makukh, Clémence Martin, Lisa Morrison, Dilip Nazareth, Jacquelien Noordhoek, Ciaran O'Neill, Elizabeth Owen, Helen Oxley, Karen S. Raraigh, Caroline Raynal, Karen Robinson, Jobst Roehmel, Carsten Schwarz, Isabelle Sermet, Michal Shteinberg, Ian Sinha, Constance Takawira, Peter van Mourik, Marieke Verkleij, Michael D. Waller, Alistair Duff. Journal of Cystic Fibrosis, 2022, ISSN 1569-1993, https://doi.org/10.1016/j.jcf.2022.10.002.
The impact of plasma 25-hydroxyvitamin D on pulmonary function and exercise physiology in cystic fibrosis: A multicentre retrospective study. Revuelta Iniesta R, Causer AJ, Arregui-Fresneda I, Connett G, Allenby MI, Daniels T, Carroll MP, Urquhart DS, Saynor ZL. J Hum Nutr Diet. 2022 Apr;35(2):363-375. doi: 10.1111/jhn.12906. Epub 2021 Jun 1. PMID: 33908093
Meconium Ileus due to GUCY2C gene mutations in three unrelated South Indian families. Varkki S, Benjamin AT, Athiyarath R, Danda S, Sowmya R, Connett G. J Cyst Fibros. 2021 Sep;20(5):e84-e86. doi: 10.1016/j.jcf.2021.03.023. Epub 2021 Apr 18. PMID: 33883099.
Soren O, Rineh A, Silva DG, Cai Y, Howlin RP, Allan RN, Feelisch M, Davies JC, Connett GJ, Faust SN, Kelso MJ, Webb JS. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2020 Jan 1;75(1):117-125. doi: 10.1093/jac/dkz378. PMID: 31682251; PMCID: PMC6910178.
Daniels TW, Rogers GB, Stressmann FA, van der Gast CJ, Bruce KD, Jones GR, Connett GJ, Legg JP, Carroll MP. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros. 2013 Jan;12(1):22-8. doi: 10.1016/j.jcf.2012.05.008. Epub 2012 Jun 18. PMID: 22717533.
Impact example:
Southampton is a key centre for the design and delivery of Phase 3 clinical trials of CF transmembrane conductance regulator modulators. We are a founding member of the UK’s CF clinical trials accelerator platform. We have extended our role to include early phase development of novel treatments to meet the needs of people with CF who have uncommon genotypes and who are not responsive to currently available therapies.